NMRA Neumora Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: NMRA

Price (delayed)

$9.22

Market cap

$1.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.63

Enterprise value

$1.09B

Highlights
The debt has contracted by 38% YoY and by 15% from the previous quarter
The company's EPS rose by 25% YoY
The net income has dropped by 80% year-on-year
Neumora Therapeutics's equity has decreased by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of NMRA
Market
Shares outstanding
158.89M
Market cap
$1.46B
Enterprise value
$1.09B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$235.66M
EBITDA
-$231.63M
Free cash flow
-$163.4M
Per share
EPS
-$3.63
Free cash flow per share
-$2.51
Book value per share
$3.07
Revenue per share
$0
TBVPS
$7.63
Balance sheet
Total assets
$496.2M
Total liabilities
$27.12M
Debt
$5.23M
Equity
$469.08M
Working capital
$453.17M
Liquidity
Debt to equity
0.01
Current ratio
19.05
Quick ratio
18.13
Net debt/EBITDA
1.6
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.2%
Return on equity
-2,123%
Return on invested capital
-174.7%
Return on capital employed
-50%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NMRA stock price

How has the Neumora Therapeutics stock price performed over time
Intraday
1.32%
1 week
1.77%
1 month
-33.04%
1 year
N/A
YTD
-45.92%
QTD
-32.95%

Financial performance

How have Neumora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$252.1M
Net income
-$235.93M
Gross margin
N/A
Net margin
N/A
Neumora Therapeutics's operating income has shrunk by 86% YoY
The net income has dropped by 80% year-on-year

Growth

What is Neumora Therapeutics's growth rate over time

Valuation

What is Neumora Therapeutics stock price valuation
P/E
N/A
P/B
3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 25% YoY
Neumora Therapeutics's equity has decreased by 9% QoQ

Efficiency

How efficient is Neumora Therapeutics business performance
The ROA has plunged by 67% YoY
NMRA's return on invested capital is down by 12% year-on-year

Dividends

What is NMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NMRA.

Financial health

How did Neumora Therapeutics financials performed over time
The company's total assets rose by 16% YoY but it fell by 9% QoQ
NMRA's current ratio is up by 16% year-on-year and by 6% since the previous quarter
The debt is 99% less than the equity
Neumora Therapeutics's debt to equity has surged by 150% YoY
The debt has contracted by 38% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.